Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry

CompletedOBSERVATIONAL

Enrollment

1,695

Participants

Timeline

Start Date

May 18, 2017

Primary Completion Date

April 17, 2024

Study Completion Date

April 17, 2024

Conditions

DyslipoproteinemiasHypercholesterolemia, FamilialFamilial Hypercholesterolemia - HomozygousFamilial Combined Hyperlipidemia

Interventions

DRUG

PCSK9 Inhibitor [EPC]

drug use according to the respective product labelling

DRUG

Standard lipid lowering therapy

drug use according to the respective product labelling

Trial Locations (3)

Klinik und Poliklinik für Kardiologie, Universitätsklinikum, Leipzig

Innere Medizin IV - Diabetologie, Endokrinologie und Nephrologie am Universitaetsklinikum, Tübingen

Nephrologisches Zentrum, Villingen-Schwenningen

All Listed Sponsors

lead

GWT-TUD GmbH

OTHER

NCT03110432 - Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry | Biotech Hunter | Biotech Hunter